Sector Gamma AS raised its position in Johnson & Johnson (NYSE:JNJ) by 88.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,116 shares of the company’s stock after acquiring an additional 26,837 shares during the quarter. Johnson & Johnson makes up approximately 1.9% of Sector Gamma AS’s portfolio, making the stock its 21st biggest position. Sector Gamma AS’s holdings in Johnson & Johnson were worth $8,503,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Nordea Investment Management AB grew its position in shares of Johnson & Johnson by 88.0% during the second quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock worth $2,382,514,000 after buying an additional 8,062,204 shares in the last quarter. BlackRock Inc. grew its position in shares of Johnson & Johnson by 0.6% during the second quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock worth $27,242,005,000 after buying an additional 1,168,129 shares in the last quarter. California Public Employees Retirement System grew its position in shares of Johnson & Johnson by 8.9% during the third quarter. California Public Employees Retirement System now owns 10,616,780 shares of the company’s stock worth $1,580,626,000 after buying an additional 864,547 shares in the last quarter. MUFG Securities EMEA plc grew its position in shares of Johnson & Johnson by 124.7% during the second quarter. MUFG Securities EMEA plc now owns 1,506,456 shares of the company’s stock worth $211,853,000 after buying an additional 836,139 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its position in shares of Johnson & Johnson by 290.9% during the second quarter. Handelsbanken Fonder AB now owns 1,114,004 shares of the company’s stock worth $156,662,000 after buying an additional 829,053 shares in the last quarter. 67.44% of the stock is owned by institutional investors.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.27% of the stock is currently owned by insiders.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The company had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. During the same quarter in the previous year, the business earned $2.12 earnings per share. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. As a group, research analysts predict that Johnson & Johnson will post 7.99 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio is currently 46.54%.
A number of brokerages have recently commented on JNJ. Cantor Fitzgerald boosted their price objective on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Raymond James restated a “buy” rating on shares of Johnson & Johnson in a research note on Friday. Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Finally, Credit Suisse Group boosted their target price on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Buy” and a consensus price target of $164.93.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Article: What is a CD ladder?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.